company background image
RDHL

RedHill Biopharma NasdaqGM:RDHL Stock Report

Last Price

US$0.27

Market Cap

US$17.1m

7D

-31.1%

1Y

-89.6%

Updated

03 Dec, 2022

Data

Company Financials +
RDHL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

RDHL Stock Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.

RedHill Biopharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RedHill Biopharma
Historical stock prices
Current Share PriceUS$0.27
52 Week HighUS$3.37
52 Week LowUS$0.25
Beta2.07
1 Month Change-59.85%
3 Month Change-69.34%
1 Year Change-89.58%
3 Year Change-95.96%
5 Year Change-94.26%
Change since IPO-97.61%

Recent News & Updates

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Recent updates

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Dec 02
RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Shareholder Returns

RDHLUS PharmaceuticalsUS Market
7D-31.1%2.4%1.5%
1Y-89.6%15.5%-14.9%

Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: RDHL underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is RDHL's price volatile compared to industry and market?
RDHL volatility
RDHL Average Weekly Movement19.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: RDHL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: RDHL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2009201Dror Ben-Asherhttps://www.redhillbio.com

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.

RedHill Biopharma Ltd. Fundamentals Summary

How do RedHill Biopharma's earnings and revenue compare to its market cap?
RDHL fundamental statistics
Market CapUS$17.12m
Earnings (TTM)-US$92.31m
Revenue (TTM)US$71.07m

0.2x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDHL income statement (TTM)
RevenueUS$71.07m
Cost of RevenueUS$35.17m
Gross ProfitUS$35.90m
Other ExpensesUS$128.21m
Earnings-US$92.31m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin50.51%
Net Profit Margin-129.88%
Debt/Equity Ratio-247.4%

How did RDHL perform over the long term?

See historical performance and comparison